Core Viewpoint - The company has received a new product certificate for feed additives from the Ministry of Agriculture and Rural Affairs of China, which will restrict other production and import applications for this new feed and feed additive for a monitoring period of five years [1] Group 1 - The company is now authorized to produce a new feed additive, which may enhance its market position in the agricultural sector [1] - The monitoring period of five years will prevent other companies from applying for production or import registration of the same new feed and feed additive, potentially reducing competition [1]

Group 1 - The core viewpoint of the article is that Garden Biologics (300401.SZ) has not yet generated revenue from its feed-grade cholesterol in the domestic market [1] - Feed-grade cholesterol is used as an additive in animal feed, with downstream applications primarily in premix and feed production manufacturers [1]

Core Viewpoint - The company has not yet generated revenue from its feed-grade cholesterol product, which is intended as an additive for animal feed [2]. Group 1: Company Information - The company, Huayuan Biological (花园生物), confirmed that its feed-grade cholesterol has not yet produced revenue domestically [2]. - The primary downstream customers for feed-grade cholesterol include premix and feed manufacturers [2].

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with significant growth potential identified by brokerage firms [1][3] - The companies with the highest target price increases include Baili Tianheng at 368.30%, Luoyang Molybdenum at 37.88%, and Sanqi Interactive Entertainment at 29.53%, representing the chemical pharmaceutical, industrial metals, and gaming industries respectively [1][3] - A total of 23 listed companies received brokerage recommendations on January 26, with companies like Jianda Co., Shouhua Gas, and Huayuan Bio receiving one recommendation each [3] Group 2 - On January 26, one company had its rating upgraded, specifically Hualu Hengsheng, which was raised from "Hold" to "Buy" by Tianfeng Securities [4][6] - The only company receiving a first-time coverage rating on January 26 was Boshi Jie, which was given a "Strong Buy" rating by China Merchants Securities [6][7]

Group 1 - The core point of the article is that Huayuan Bio has reported its total number of shareholders as of January 20, 2026, which stands at 26,019 households [2]

Group 1 - The core viewpoint of the article is that Huayuan Biological clarified its product offerings, stating that it sells feed-grade cholesterol and does not involve premixes [2] Group 2 - The company engaged with investors through an interactive platform to address inquiries regarding its product line [2] - The clarification aims to provide transparency about the nature of the products sold by the company [2]

证券日报网讯1月23日，花园生物（300401）在互动平台回答投资者提问时表示，公司根据市场需求合 理统筹产能安排。截至2026年1月20日，公司股东总户数为26019户。 ...

Group 1 - The core viewpoint of the article is that Garden Biologics (300401.SZ) clarified on its investor interaction platform that the products it sells are feed-grade cholesterol and do not involve premixes [1] Group 2 - The company is focused on the production and sale of feed-grade cholesterol, indicating a specific niche within the animal nutrition industry [1] - The clarification provided by the company may help to address any potential misconceptions regarding its product offerings [1]

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2026-008 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 关于"花园转债"回售结果的公告 本次"花园转债"回售不会对公司现金流、资产状况和股本情况产生影响。 三、本次可转换公司债券回售的后续事项 浙江花园生物医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏 一、本次可转换公司债券回售的公告情况 浙江花园生物医药股份有限公司（以下简称"公司"）分别于2026年1月8日、1月 12日和1月15日在巨潮资讯网（www.cninfo.com.cn）披露了《关于"花园转债"回售的 第一次提示性公告》（公告编号：2026-002）、《关于"花园转债"回售的第二次提示 性公告》（公告编号：2026-004）、《关于"花园转债"回售的第三次提示性公告》 （公告编号：2026-006），"花园转债"持有人可以在回售申报期内将持有的"花园转 债"全部或部分回售给公司。回售价格为人民币100.855元/张（含息、税），回售申报 期为2026 ...

Group 1 - Garden Biologics experienced a stock price increase of 3.57% on January 15, with a trading volume of 828 million yuan [1] - The company had a net financing buy of -2.61 million yuan on the same day, with a total financing and margin balance of 732 million yuan [1] - The financing balance of Garden Biologics is 730 million yuan, accounting for 8.13% of its circulating market value, which is above the 80th percentile level over the past year [1] Group 2 - As of December 31, the number of shareholders for Garden Biologics was 26,200, a decrease of 12.35% from the previous period [2] - For the period from January to September 2025, the company reported a revenue of 936 million yuan, a year-on-year decrease of 0.20%, and a net profit attributable to shareholders of 234 million yuan, down 3.07% year-on-year [2] - The company has distributed a total of 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed in the last three years [2]